Changes in liver lysosome fragility, erythrocyte membrane stability, and local and systemic lysosomal enzyme levels in adjuvant-induced polyarthritis.
D000135:Acid Phosphatase / Q000097:blood / Q000378:metabolism; D000276:Adjuvants, Immunologic; D000818:Animals; D001168:Arthritis / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism*; D005528:Foot; D005966:Glucuronidase / Q000097:blood / Q000378:metabolism; D006461:Hemolysis; D006614:Hindlimb / Q000201:enzymology; D007213:Indomethacin / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism*; D008247:Lysosomes / Q000201:enzymology / Q000378:metabolism*; D009169:Mycobacterium tuberculosis; D009996:Osmotic Fragility; D010248:Paramethasone / Q000627:therapeutic use; D010653:Phenylbutazone / Q000627:therapeutic use; D051381:Rats; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000135:Acid Phosphatase; D005966:Glucuronidase; D010653:Phenylbutazone; D010248:Paramethasone; D007213:Indomethacin